Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 280, Issue 2 49-2, 2001, Pages

  Saijonmaa, Outi ^a,b   Nyman, Tuulikki ^a   Kosonen, Riikka ^a   Fyhrquist, Frej ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

Author keywords

Human umbilical vein endothelial cells; Regulation; Signal transduction

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; ARGININE METHYL ESTER; CYCLIC GMP; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE; HERBIMYCIN; INDOMETACIN; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RESVERATROL; VASCULOTROPIN; ZAPRINAST;

ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0035012137     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.2001.280.2.h885     Document Type: Article

References (31)

1. Abedi H and Zachary I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem 272: 15442-15451, 1997.
2. Chobanian AC, Haudenschild C, Nickerson C, and Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 15: 327-331, 1990.
3. Chua CC, Hamdy RC, and Chua BHL. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1401: 187-194, 1998.
4. Couffinhal T, Kearney M, Witzenbichler B, Chen D, Murohara T, Losordo DW, Symes J, and Isner JM. Vascular endothelial growth factor/vascular permeability factor (VEGF/ VPF) in normal and atherosclerotic human arteries. Am J Pathol 150: 1673-1685, 1997.
5. Dahlöf B, Pennert K, and Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients-a metaanalysis of 109 treatment studies. Am J Hypertens 5: 95-110, 1992.
6. De Vries C, Escobedo JA, Ueno H, Houk K, Ferrara N, and Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991, 1992.
7. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, and Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 94: 2756-2767, 1996.
8. Dzau VJ and Pratt RE. Cardiac, vascular, and intrarenal renin-angiotensin systems in normal physiology and disease. In: The Renin-Angiotensin System, edited by Robertson I and Nicholls G. London: Gower Medical, 1993, vol. 1, p. 42.1-42.11.
9. Fabre JE, Rivard A, Magner M, Silver M, and Isner JM. Tissue inhibition of angiotensin converting enzyme activity stimulates angiogenesis in vivo. Circulation 99: 3043-3049, 1999.
10. Ferrara N and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrine Rev 18: 4-25, 1997.
11. Fyhrquist F, Tikkanen I, Grönhagen-Riska C, Hortling L, and Hichens M. Inhibitor binding assay for angiotensin converting enzyme. Clin Chem 30: 696-700, 1984.
12. He H, Venema V, Gu X, Venema R, Marrero M, and Caldwell R. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through Flk-1/ KDR activation of c-Src. J Biol Chem 274: 25130-25135, 1999.
13. Hewett P and Murray JC. Coexpression of flt-1, flt-4 and KDR in freshly isolated and cultured human endothelial cells. Biochem Biophys Res Commun 221: 697-702, 1996.
14. Hood JD, Meininger CJ, Ziche M, and Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol Heart Circ Physiol 274: H1054-H1058, 1998.
15. Jackson B, Cubela R, and Johnston C. Characterization of angiotensin converting enzyme from rat tissue by radio-inhibitor binding studies. Clin Exp Pharmacol Physiol 13: 681-689, 1986.
16. Jaffe E, Nachman R, Becker C, and Minick R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52: 2745-2756, 1973.
17. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, and Robertson JW. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352: 179-184, 1998.
18. Ohishi M, Ueda M, Rakugi H, Naruko T, Kojima A, Okamura A, Higaki J, and Ogihara T. Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens 15: 1295-1302, 1997.
19. Otani A, Takagi H, Suzuma K, and Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 82: 619-628, 1998.
20. Papapetropoulos A, Garcia-Cardena G, Madri JA, and Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100: 3131-3139, 1997.
21. Ponte P, Ng SY, Engel J, Gunning P, and Kedes L. Evolutionary conservation in the untranslated regions of actin mR-NAs: DNA sequence of a human β-actin cDNA. Nucleic Acids Res 12: 1687-1696, 1984.
22. Ruef J, Hu ZY, Yin LY, Wu Y, Hanson SR, Kelly AB, Harker LA, Rao GN, Runge MS, and Patterson C. Induction of vascular endothelial growth factor in balloon-injured baboon arteries. A novel role for reactive oxygen species in atherosclerosis. Circ Res 81: 24-33, 1997.
23. Saijonmaa O and Fyhrquist F. Upregulation of angiotensin converting enzyme by atrial natriuretic peptide and cyclic GMP in human endothelial cells. Cardivasc Res 40: 206-210, 1998.
24. Skidgel R and Erdös E. Biochemistry of angiotensin I-converting enzyme. In: The Renin-Angiotensin System, edited by Robertson I and Nicholls G. London: Gower Medical, 1993, vol. 1, p. 10.1-10.10.
25. Smith W. Molecular biology of prostanoid biosynthetic enzymes and receptors. Adv Exp Med Biol 400B: 989-1011, 1997.
26. Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, Tregear G, and Corvol P. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA 85: 9386-9390, 1988.
27. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, and Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Commun 187: 1579-1586, 1992.
28. Villard E, Alonso A, Agrapart M, Challah M, and Soubrier F. Induction of angiotensin I-converting enzyme transcription by a protein kinase C-dependent mechanism in human endothelial cells. J Biol Chem 273: 25191-25197, 1998.
29. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, and Bouck NP. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rate. J Clin Invest 98: 671-679, 1996.
30. Watanabe K, Lam G, Keresztes R, and Jaffe E. Lipopolysaccharides decrease angiotensin converting enzyme activity expressed by cultured human endothelial cells. J Cell Physiol 150: 433-39, 1992.
31. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, and Takagi H. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 98: 2018-2026, 1996.